PATENT CLAIM ANALYSIS

Application Number: 16204166
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-07
Patent Classification: ["544", "242000"]

Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claim (Index 19):
The method of  claim 12 , wherein the administering of the compound causes a lower incidence of viral mutation and/or viral resistance than the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, inducer of cellular viral RNA sensor, therapeutic vaccine, antiviral compounds of distinct or unknown mechanism, and combination thereof.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 98.0
- Lexical Diversity: 1.73016
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15209150', '15088517', '15216124', '16194608', '15421777']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8505595614214914
- 35 USC 102 Novelty (BERT): 0.5458926301678626
- Combined Prediction Score: 0.8200928682961285
- Mean Citation Score: 392.076462
- Max Citation Score: 423.04852
- Similarity Product: 346.2494968020057

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test